NORTHWEST BIOTHERAPEUTICS INC (NWBO) Form 8-K — Oct 30, 2026
Northwest Biotherapeutics entered into a $5,505,000 commercial loan agreement with Streeterville Capital, LLC on October 26, 2026, with proceeds earmarked for ongoing business operations. The loan carries an 8% annual interest rate with a ten percent original issue discount, matures in 22 months, and requires no repayments for the first 8 months before amortizing in 14 monthly installments of principal at 110% of the pro rata amount plus interest starting June 26, 2027.
Key figures
- Debt Amount
- 5505000
- Interest Rate
- 8
- Maturity Date
- 22-month maturity from October 26, 2026
- Amortization
- 14 equal monthly installments of principal at 110% of pro rata amount plus interest, beginning June 26, 2027
- Prepayment charge
- 10%
- Original issue discount
- 10%
- Repayment holiday months
- 8
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.